ArticleBMC pediatrics2025
Timing of treatment with oral propranolol for infantile hemangioma.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Determinants of proliferation and involution in infantile hemangioma: macrophage crosstalk, endothelial plasticity, and metabolic rewiring.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEarly oral propranolol for infantile hemangioma (IH) can improve the success rate. However, few studies have been conducted on the specific age threshold for initiating treatment with propranolol. This study aimed to determine the cutoff value of treatment success for IH with oral propranolol.
methodsThis was a retrospective study involving 207 patients with IH and clinical data.The primary outcome measure was treatment success with oral propranolol at months 6 to 12.
resultsMultivariate analysis showed that age at treatment initiation (P < 0.001), high-risk IH (P = 0.002), and segmental IH (P = 0.012) were independent risk factors for treatment unsuccess with oral propranolol at months 6 to 12. Receiver operating characteristic (ROC) curve analysis indicated that the cutoff value for age at treatment initiation was 69.5 days for all patients, 65.5 days for patients with segmental IH or high-risk IH, and 93.5 days for patients with non-high-risk and nonsegmental IH. Patients who started treatment before 69.5 days had a success rate of 73.8%, which was higher than the 28.4% success rate of patients who started treatment after 69.5 days. The median time to treatment success for patients who started treatment before 69.5 days was 11.5 months, which was shorter than the 15 months for patients who started treatment after 69.5 days.
conclusionThe initiation of treatment for IH with oral propranolol before 70 days of age can improve the success rate and shortens treatment duration, especially for segmental IH and high-risk IH. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.